-
公开(公告)号:US20230417662A1
公开(公告)日:2023-12-28
申请号:US18276082
申请日:2021-12-08
Applicant: SHIMADZU CORPORATION
Inventor: Takashi ONO , Masahiro IHARA , Hiromasa MARUNO , Satoshi MATSUOKA , Eri MATSUTANI , Yusuke KOGA
IPC: G01N21/3563
CPC classification number: G01N21/3563 , G01N2021/3595
Abstract: One mode of an optical inspection apparatus according to the present invention is an optical inspection apparatus for optically inspecting an object, the optical inspection apparatus including: a biasing section (20) configured to apply, to a group of objects (23A) on a stage, a force for moving the group of objects away with respect to the stage (22); a catching section (24) including an adhesion portion (241) to which an object in the group of objects moved from the stage adheres; and an analysis section (3) configured to optically analyze the object caught by the catching section. This makes it possible to efficiently and satisfactorily perform optical analysis of individual microplastics by eliminating manual work of picking up the microplastics one by one.
-
2.
公开(公告)号:US20180021748A1
公开(公告)日:2018-01-25
申请号:US15547687
申请日:2015-02-04
Applicant: Shimadzu Corporation
Inventor: Eri MATSUTANI , Eiichi OZEKI , Takashi KAWABE
Abstract: The present invention relates to a method and an apparatus both for producing molecular assemblies of an amphiphilic block polymer. The method of the present invention includes: applying a polymer solution (45) containing an amphiphilic block polymer and a solvent in a layered shape on a planar base member (11) in a film forming part (40); forming a polymer film on the base member (13) by removing the solvent from the coated layer of the solution in a drying part (30); and producing molecular assemblies by bringing the polymer film into contact with a water-based liquid (55) in a molecular assembly forming part (50). The amphiphilic block polymer has a hydrophilic block chain and a hydrophobic block chain. The hydrophilic block chain preferably has 20 or more sarcosine units, and the hydrophobic block chain preferably has 10 or more lactic acid units.
-
公开(公告)号:US20180264119A1
公开(公告)日:2018-09-20
申请号:US15760414
申请日:2016-08-29
Applicant: Shimadzu Corporation
Inventor: Takashi KAWABE , Eri MATSUTANI , Hayato MATSUI
CPC classification number: A61K47/34 , A61K9/5123 , A61K9/5146 , C08G63/6852 , C08G63/912 , C08J3/05 , C08J3/12 , C08J2300/16 , C08J2367/04 , C08J2371/02 , C08J2377/04 , C08L67/04 , C08L71/02 , C08L77/04 , C08L2201/06 , C08K5/17
Abstract: The nanoparticles of the present invention consist of a molecular aggregate containing an amphipathic block polymer that has a hydrophilic block and a hydrophobic block. It is preferable that the amphipathic block polymer be biodegradable. The nanoparticles of the present invention are obtained by granulating into particles an amphipathic block polymer in the presence of an amino acid whose isoelectric point is 7 or less. In one embodiment, the granulation is done by bringing a solution containing an amphipathic block polymer or the dried product thereof into contact with an aqueous liquid. Granulation can be done in the presence of an amino acid by including an amino acid whose isoelectric point is 7 or less in either a solution that contains an amphipathic block polymer or in an aqueous liquid, or in both.
-
公开(公告)号:US20170151335A1
公开(公告)日:2017-06-01
申请号:US15312985
申请日:2015-05-21
Applicant: Shimadzu Corporation
Inventor: Kenichi SUZUKI , Haruki NAKAGAWA , Yoshihiro YAMAKITA , Eiichi OZEKI , Takashi KAWABE , Eri MATSUTANI
CPC classification number: A61K47/34 , A61K9/0014 , A61K9/107 , A61K9/1075 , A61K9/50 , A61K31/13 , A61K31/325 , A61K31/47 , C08G63/912 , C08G2230/00
Abstract: Provided is a skin external preparation including a drug and nanometer-size molecular assemblies. The molecular assemblies contain an amphiphilic block copolymer having a hydrophilic block chain including a sarcosine-derived structural unit and a hydrophobic block chain including a hydroxy acid-derived structural unit. The skin external preparation according to the present invention may reduce skin irritation caused by the drug, be very safe, and have excellent pharmacological effects, even when a drug that is generally difficult to be transdermally administered due to its strong skin irritation is contained therein.
-
-
-